Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years. 

By Gwendolyn Wu • Aug. 10, 2026

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

By BioPharma Dive staff • Aug. 7, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Latigo IPO raises nearly $350M for pain drug development

The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.

By Jacob Bell • Aug. 7, 2026

Replimune rebounds to win FDA approval of melanoma drug

The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.

By Jonathan Gardner • Aug. 6, 2026

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.” 

By Ben Fidler • Aug. 6, 2026

With $263M, LifeMine unearths a new drug for organ transplants

Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs. 

By Gwendolyn Wu • Aug. 6, 2026

Cardiac drug developer Braveheart banks more than $382M in IPO

Braveheart’s offering was the largest among four biotech IPOs that collectively raised more than $1 billion from public investors last week.

By Gwendolyn Wu • Updated Aug. 6, 2026

Attovia adds to biotech IPO momentum with $289M offering

The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.

By Jonathan Gardner • Aug. 5, 2026

Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

By Delilah Alvarado , Ben Fidler • Aug. 5, 2026

A COPD drug from China draws $115M in venture funding

Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.

By Gwendolyn Wu • Aug. 5, 2026

Vertex’s biggest overhang: a rival 50 times smaller

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.

By Jacob Bell • Aug. 4, 2026

J&J pharma leader to retire; Krystal slumps on gene therapy miss

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

By BioPharma Dive staff • Aug. 4, 2026

BioNTech taps Sobi executive Oelkers as its next CEO

Guido Oelkers will guide BioNTech’s ongoing transition into an oncology-focused biotech, while co-founder and longtime leader Ugur Sahin prepares to join a fledgling mRNA startup.

By Delilah Alvarado • Aug. 3, 2026

Supernus, Indivior merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.

By Jonathan Gardner • Aug. 3, 2026

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

By BioPharma Dive staff • July 31, 2026

Replimune melanoma drug wins support of FDA panel

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

By Jonathan Gardner • July 30, 2026

Alnylam plunges as earnings deliver ‘one-two punch’

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

By Ben Fidler , Jacob Bell • July 30, 2026

MapLight CEO on what investors missed in the biotech’s schizophrenia data

Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."

By Jacob Bell • July 29, 2026

Caldera, Vidya add to recent flurry of biotech mergers

The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.

By Gwendolyn Wu • July 29, 2026

AbCellera, Vertex partner on next-gen T-cell engagers

The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.

By Delilah Alvarado • July 29, 2026

FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data

Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.

By BioPharma Dive staff • July 29, 2026

An eye drug biotech banks $118M and stocks its executive suite

Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.

By Gwendolyn Wu • July 28, 2026

MapLight dives despite positive data for schizophrenia drug

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.

By Jacob Bell • July 27, 2026

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

By Delilah Alvarado • July 27, 2026

FDA scientists question Capricor data; Legend CEO steps down

Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble.

By Ben Fidler • July 27, 2026